XOMA’s main strengths include an exceptionally high gross margin business model, a differentiated position as a biotech royalty aggregator, and a broad, diversified portfolio of royalty and milestone interests. The company has demonstrated the ability to source creative deals, raise significant external capital when needed, and maintain a meaningful cash buffer. Its scientific background and transaction expertise give it an edge in assessing and structuring complex biotech assets.

Key risks center on persistent operating and net losses, negative free cash flow, and a growing reliance on debt to fund operations and acquisitions. Rising leverage and declining equity reduce financial resilience, while a heavier dependence on intangibles ties more of the balance sheet to uncertain future drug success. On the business side, XOMA is exposed to the clinical, regulatory, and commercial risks of many third-party programs, as well as competitive pressure from other royalty and specialty finance firms.

Looking ahead, the company’s trajectory will largely be determined by whether its expanded royalty portfolio can mature into a stable and growing stream of cash flows before financial pressures build further. If enough late-stage and recently approved assets ramp successfully, XOMA could see a meaningful improvement in profitability and cash generation over time. Conversely, continued portfolio setbacks or delays, combined with ongoing cash burn and higher interest costs, would keep the financial profile strained. Overall, the story is one of a strategically interesting model with clear long-term optionality, but also material execution and balance-sheet risk in the nearer term.